Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

Simon J. Hall, Steven E. Mutchnik, Guang Yang, Terry L. Timme, Yasutomo Nasu, Chris H. Bangma, Savio L C Woo, Mohammed Shaker, Timothy C. Thompson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Adenovirus-mediated transduction of the herpes simplex thymidine kinase gene (HSV-tk) in conjunction with ganciclovir (GCV) has been shown to result in significant growth suppression and to enhance survival in a model of mouse prostate cancer. However, this therapeutic activity is not sustained, because in most cases tumors eventually regrow and ultimately cause the death of the host. Androgen ablation, an inducer of apoptosis in prostate cells which is used widely as palliative therapy in patients with prostate cancer, was combined with HSV-tk plus GCV using an androgen-sensitive mouse prostate cancer cell line. The combination of castration and HSV-tk plus GCV led to markedly enhanced tumor growth suppression in both subcutaneous and orthotopic models compared with either treatment alone and resulted in an enhanced survival in which combination-treated animals lived twice as long as controls in the subcutaneous model and over 50% longer than controls in the orthotopic model. Further analysis of apoptotic activity demonstrated high levels of apoptosis only in combined androgen ablation and HSV-tk plus GCV-treated tumors after 14 days of growth in an androgen-depleted environment and 8 days after HSV-tk plus GCV therapy. At this time, the apoptotic index, but not the percent of necrotic tissue, was significantly higher for combination therapy-treated tumors relative to control-treated tumors or either treatment alone. These data indicate that the therapeutic effects of androgen ablation and HSV-tk plus GCV are cooperative and that increased apoptosis may, in part, underlie these activities.

Original languageEnglish
Pages (from-to)54-63
Number of pages10
JournalCancer Gene Therapy
Volume6
Issue number1
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Ganciclovir
Thymidine Kinase
Therapeutic Uses
Simplexvirus
Adenoviridae
Genetic Therapy
Androgens
Prostatic Neoplasms
Neoplasms
Apoptosis
Growth
Therapeutics
Herpes Simplex
Survival
Castration
Palliative Care
Prostate
Cause of Death
Cell Line
Genes

Keywords

  • Androgen ablation
  • Gene therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. / Hall, Simon J.; Mutchnik, Steven E.; Yang, Guang; Timme, Terry L.; Nasu, Yasutomo; Bangma, Chris H.; Woo, Savio L C; Shaker, Mohammed; Thompson, Timothy C.

In: Cancer Gene Therapy, Vol. 6, No. 1, 1999, p. 54-63.

Research output: Contribution to journalArticle

Hall, Simon J. ; Mutchnik, Steven E. ; Yang, Guang ; Timme, Terry L. ; Nasu, Yasutomo ; Bangma, Chris H. ; Woo, Savio L C ; Shaker, Mohammed ; Thompson, Timothy C. / Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. In: Cancer Gene Therapy. 1999 ; Vol. 6, No. 1. pp. 54-63.
@article{befdce5e89ba40b6b96715816674d366,
title = "Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer",
abstract = "Adenovirus-mediated transduction of the herpes simplex thymidine kinase gene (HSV-tk) in conjunction with ganciclovir (GCV) has been shown to result in significant growth suppression and to enhance survival in a model of mouse prostate cancer. However, this therapeutic activity is not sustained, because in most cases tumors eventually regrow and ultimately cause the death of the host. Androgen ablation, an inducer of apoptosis in prostate cells which is used widely as palliative therapy in patients with prostate cancer, was combined with HSV-tk plus GCV using an androgen-sensitive mouse prostate cancer cell line. The combination of castration and HSV-tk plus GCV led to markedly enhanced tumor growth suppression in both subcutaneous and orthotopic models compared with either treatment alone and resulted in an enhanced survival in which combination-treated animals lived twice as long as controls in the subcutaneous model and over 50{\%} longer than controls in the orthotopic model. Further analysis of apoptotic activity demonstrated high levels of apoptosis only in combined androgen ablation and HSV-tk plus GCV-treated tumors after 14 days of growth in an androgen-depleted environment and 8 days after HSV-tk plus GCV therapy. At this time, the apoptotic index, but not the percent of necrotic tissue, was significantly higher for combination therapy-treated tumors relative to control-treated tumors or either treatment alone. These data indicate that the therapeutic effects of androgen ablation and HSV-tk plus GCV are cooperative and that increased apoptosis may, in part, underlie these activities.",
keywords = "Androgen ablation, Gene therapy, Prostate cancer",
author = "Hall, {Simon J.} and Mutchnik, {Steven E.} and Guang Yang and Timme, {Terry L.} and Yasutomo Nasu and Bangma, {Chris H.} and Woo, {Savio L C} and Mohammed Shaker and Thompson, {Timothy C.}",
year = "1999",
language = "English",
volume = "6",
pages = "54--63",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

AU - Hall, Simon J.

AU - Mutchnik, Steven E.

AU - Yang, Guang

AU - Timme, Terry L.

AU - Nasu, Yasutomo

AU - Bangma, Chris H.

AU - Woo, Savio L C

AU - Shaker, Mohammed

AU - Thompson, Timothy C.

PY - 1999

Y1 - 1999

N2 - Adenovirus-mediated transduction of the herpes simplex thymidine kinase gene (HSV-tk) in conjunction with ganciclovir (GCV) has been shown to result in significant growth suppression and to enhance survival in a model of mouse prostate cancer. However, this therapeutic activity is not sustained, because in most cases tumors eventually regrow and ultimately cause the death of the host. Androgen ablation, an inducer of apoptosis in prostate cells which is used widely as palliative therapy in patients with prostate cancer, was combined with HSV-tk plus GCV using an androgen-sensitive mouse prostate cancer cell line. The combination of castration and HSV-tk plus GCV led to markedly enhanced tumor growth suppression in both subcutaneous and orthotopic models compared with either treatment alone and resulted in an enhanced survival in which combination-treated animals lived twice as long as controls in the subcutaneous model and over 50% longer than controls in the orthotopic model. Further analysis of apoptotic activity demonstrated high levels of apoptosis only in combined androgen ablation and HSV-tk plus GCV-treated tumors after 14 days of growth in an androgen-depleted environment and 8 days after HSV-tk plus GCV therapy. At this time, the apoptotic index, but not the percent of necrotic tissue, was significantly higher for combination therapy-treated tumors relative to control-treated tumors or either treatment alone. These data indicate that the therapeutic effects of androgen ablation and HSV-tk plus GCV are cooperative and that increased apoptosis may, in part, underlie these activities.

AB - Adenovirus-mediated transduction of the herpes simplex thymidine kinase gene (HSV-tk) in conjunction with ganciclovir (GCV) has been shown to result in significant growth suppression and to enhance survival in a model of mouse prostate cancer. However, this therapeutic activity is not sustained, because in most cases tumors eventually regrow and ultimately cause the death of the host. Androgen ablation, an inducer of apoptosis in prostate cells which is used widely as palliative therapy in patients with prostate cancer, was combined with HSV-tk plus GCV using an androgen-sensitive mouse prostate cancer cell line. The combination of castration and HSV-tk plus GCV led to markedly enhanced tumor growth suppression in both subcutaneous and orthotopic models compared with either treatment alone and resulted in an enhanced survival in which combination-treated animals lived twice as long as controls in the subcutaneous model and over 50% longer than controls in the orthotopic model. Further analysis of apoptotic activity demonstrated high levels of apoptosis only in combined androgen ablation and HSV-tk plus GCV-treated tumors after 14 days of growth in an androgen-depleted environment and 8 days after HSV-tk plus GCV therapy. At this time, the apoptotic index, but not the percent of necrotic tissue, was significantly higher for combination therapy-treated tumors relative to control-treated tumors or either treatment alone. These data indicate that the therapeutic effects of androgen ablation and HSV-tk plus GCV are cooperative and that increased apoptosis may, in part, underlie these activities.

KW - Androgen ablation

KW - Gene therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0032618858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032618858&partnerID=8YFLogxK

M3 - Article

C2 - 10078964

AN - SCOPUS:0032618858

VL - 6

SP - 54

EP - 63

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -